Skip to Content

Merck KGaA

MRK: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€626.00FmcsbqXnbbcmfbsb

Merck KGaA Expects to Continue Benefiting From COVID-19 in 2022; Shares Moderately Rich

Narrow-moat Merck KGaA revealed strong fourth-quarter operating results that continued to be helped by pandemic-related activities. Given our view that Merck's prospects may decelerate in the intermediate term when the pandemic turns into an endemic situation, we are keeping our fair value estimate intact and continue to view the shares as moderately rich.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center